echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Winbond Health's wholly-owned subsidiary methylprednisolone sodium succinate for injection passed the consistency evaluation

    Winbond Health's wholly-owned subsidiary methylprednisolone sodium succinate for injection passed the consistency evaluation

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 26, Winbond Health issued an announcement stating that its wholly-owned subsidiary Winbond Pharmaceuticals had recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for injection of methylprednisolone sodium succinate.
    "

    .

    Methylprednisolone sodium succinate for injection is a kind of freeze-dried powder of glucocorticoid drugs.
    It has strong anti-inflammatory, anti-allergic, anti-shock, and immunosuppressive effects.
    It is clinically used in acute and critically ill patients.
    Period, and maintenance treatment after first aid

    .
    Mainly used for anti-inflammatory therapy, immunosuppressive therapy, blood disease, tumor, shock therapy, endocrine disorders

    .
    It is especially suitable for disease states that require rapid treatment with strong action and quick onset

    .

    According to the enlarged version of the hospital data (including urban public hospitals, county-level public hospitals, urban community hospitals, and township health centers) on Minai.
    com, the sales of methylprednisolone sodium succinate for injection in 2019 and 2020 are about approximately 2.
    4 billion yuan and 1.
    9 billion yuan, including specifications of 20mg, 40mg, 125mg, 250mg, 500mg, 1.
    0g, 2.
    0g, of which the market-leading specification is 40mg.
    The sales of this specification in 2019 and 2020 are about It was 1.
    73 billion yuan and 1.
    341 billion yuan

    .
    Winbond Pharmaceuticals currently has 40mg and 500mg methylprednisolone sodium succinate specifications for injection.
    The 40mg specification that passed the generic drug consistency evaluation this time was passed.
    The 500mg specification passed the consistency evaluation in June 2021

    .

    Winbond Pharmaceuticals, as the third company to pass the consistency evaluation of methylprednisolone sodium succinate (40mg) for injection, will be eligible to participate in the national centralized procurement
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.